Penumbra, Inc.
PEN Healthcare Medical Devices
Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.
- Revenue
- +15.6%
- EPS
- −8.29%
- Free cash flow
- −37.2%
- Total debt
- −10.3%
Quarter to September 2026, against a year earlier
Follow PEN
Alert me
Penumbra, Inc. (PEN) P/B ratio
As of 5 November 2026, Penumbra, Inc. (PEN) trades at a P/B ratio of 8.0×. Over the past ten years it has ranged from 0.0× (September 2015) to 17.4× (April 2021); the current reading is higher than 36% of that period. That is above the Medical Devices industry median of 2.5× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 8.5× | 6.32% |
| FY2024 | 8.0× | (0.01%) |
| FY2023 | 8.0× | (4.86%) |
| FY2022 | 8.4× | (24.32%) |
| FY2021 | 11.1× | 12.83% |
| FY2020 | 9.8× | (16.51%) |
| FY2019 | 11.8× | 19.03% |
| FY2018 | 9.9× | 32.71% |
| FY2017 | 7.4× | 1.65% |
| FY2016 | 7.3× | 163.77% |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 7.9× | (2.42%) |
| Jun 2026 | 8.1× | (7.23%) |
| Mar 2026 | 8.8× | 3.24% |
| Dec 2025 | 8.5× | 16.33% |
| 43 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| BIO Bio-Rad Laboratories, Inc. compare | 1.3× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 1.3× |
| GMED Globus Medical, Inc. compare | 2.3× |
| SNN Smith & Nephew SNATS, Inc. compare | 2.8× |
| BRKR Bruker Corporation compare | 3.7× |
| PODD Insulet Corporation compare | 7.6× |
| PEN Penumbra, Inc. | 8.0× |
| TXG 10x Genomics compare | 9.2× |
| GKOS Glaukos Corporation compare | 18.1× |
| Medical Devices industry median | 2.5× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on PEN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement